Metavia Inc (MTVA) Stock Price, Quote & News

Company Profile

MetaVia Inc., a clinical-stage biotechnology company, focuses on developing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, as well as completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus; and DA-1726, a novel oxyntomod...

Industry: Biotechnology

Sector: Healthcare

Phone: 857 702 9600

Website: www.metaviatx.com

Address:

545 Concord Avenue, Suite 210, Cambridge, United States

Kertzi Apr. 11 at 5:31 AM

$MTVA PR → dilution = well-known retail trap (scam) Few days ago they issued and printed another million shares. Toxic lenders were not able to dump these shares with no volume, and yesterday MetaVia publishes a completely non-athletic PR: “MetaVia Doses the First Patient” – WOW! Did you really?! And so Armistice successfully dumped their freshly printed shares. Yet, we are still waiting for actual impactful news like status with FDA — or is it so that FDA is not interested in talking with a tiny pharma agent for a Korean company, who themselves are hiding behind?

0 · Reply

Invest2Create Apr. 10 at 10:01 PM

I’m watching $MTVA. Traders have reached positively to the continuation of a trial on an obesity drug, with $MTVA rising 18.49% to 1.41 in the Regular Session. MetaVia looks to be starting a good “First Step” towards a larger move, quite likely after a test of its 20 Day SMA support at 1.34 in the coming days. Upside targets are the 200 Day SMA at 6.67 offering a potential 373% gain, with analysts’ price targets as high as 20 with a potential 1,318% gain. But wait for the retest of the 20 Day SMA over the coming week. $MTVA has a history of retesting SMA support levels before making big moves up, unless it is filling down gaps, which is not the case here.

0 · Reply

Coletrain02 Apr. 10 at 9:50 PM

$MTVA

0 · Reply

Joefreeagent Apr. 10 at 9:23 PM

$MTVA if you didn't get out before be happy with 20 cents and get out.

1 · Reply

SkOtTheBoOt Apr. 10 at 7:39 PM

$MTVA what about the people who are down over 80% in the last three months 🤔

0 · Reply

focafoca99 Apr. 10 at 6:07 PM

$MTVA dosed the first patient in the higher-dose part of its Phase 1 DA-1726 obesity study, testing titration paths to 48 mg and 64 mg.

0 · Reply

BioTuesdays Apr. 10 at 4:24 PM

$MTVA has dosed the first patient in Part 3 of its Phase 1 clinical trial evaluating DA-1726, a novel dual oxyntomodulin analog targeting both GLP-1 and glucagon receptors. https://biotuesdays.com/2026/04/10/metavia-doses-first-patient-in-study-of-da-1726-in-obesity/

0 · Reply

TheGreekOptions Apr. 10 at 4:05 PM

$MTVA Shares @ 1.35

0 · Reply

Mazhabib Apr. 10 at 3:20 PM

$MTVA

0 · Reply

DARKP00L Apr. 10 at 2:02 PM

$MTVA 08:35 on Apr. 10 2026 MetaVia Says First Patient Dosed In Part 3 Of Phase 1 Clinical Trial Evaluating DA-1726, Dual Oxyntomodulin Analog Targeting Both GLP-1 And Glucagon Receptors #tradeideas

0 · Reply

MetaVia Doses the First Patient in Higher-Dose Phase 1 Study of DA-1726, Its GLP-1 and Glucagon Dual Agonist for the Treatment of Obesity

Mar 26, 2026, 8:31 AM EDT - 16 days ago

MetaVia Reports Year End 2025 Financial Results and Provides Corporate Update

Mar 18, 2026, 8:00 AM EDT - 24 days ago

MetaVia Advances GLP-1-Based Obesity Program with IRB Approval for Higher-Dose Phase 1 Studies of DA-1726, a GLP-1 and Glucagon Dual Agonist Demonstrating Best-in-Class Potential for Weight Loss and Glucose Control

Mar 12, 2026, 9:01 AM EDT - 4 weeks ago

MetaVia Expands Global Patent Protection for Vanoglipel, Supporting Metabolic and Liver Disease Therapy Through 2035

Mar 4, 2026, 8:31 AM EST - 5 weeks ago

MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Life Sciences Virtual Investor Forum

Feb 17, 2026, 9:01 AM EST - 7 weeks ago

MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Emerging Growth Conference

Feb 13, 2026, 12:39 PM EST - 2 months ago

MetaVia Secures Dozens Of Patents Through 2041 For Obesity Drug

Feb 13, 2026, 8:31 AM EST - 2 months ago

MetaVia Builds Comprehensive Global Patent Protection for DA-1726, Securing Exclusive Rights to Novel Obesity and Metabolic Therapy Through 2041

Feb 4, 2026, 8:00 AM EST - 2 months ago

MetaVia Announces Positive AI-Modeling Results from its Ongoing Syntekabio Collaboration, Confirming Key Therapeutic Targets for Vanoglipel

Jan 16, 2026, 4:01 PM EST - 3 months ago

MetaVia Announces the Closing of $9.3 Million Underwritten Public Offering, Including Full Exercise of Allotment Option

Jan 15, 2026, 9:32 AM EST - 3 months ago

MetaVia Announces the Pricing of $8.1 Million Underwritten Public Offering

Jan 5, 2026, 8:30 AM EST - 3 months ago

MetaVia Reports Positive Statistically Significant Results from Its Phase 1b Clinical Trial of DA-1726 In Metabolic Disease - Demonstrating Strong Glycemic Response, Significant Direct Hepatic Effects, Robust Weight Loss and Favorable Safety Profile

Dec 29, 2025, 8:31 AM EST - 3 months ago

MetaVia to Participate in and Sponsor the 10th Annual MASH-TAG 2026 Conference

Dec 22, 2025, 8:31 AM EST - 3 months ago

MetaVia Regains Compliance with Nasdaq Minimum Bid Price Requirement

Dec 2, 2025, 8:45 AM EST - 4 months ago

MetaVia Inc. Announces 1-for-11 Reverse Stock Split

Nov 7, 2025, 8:31 AM EST - 5 months ago

MetaVia Presents Positive New Phase 2a Data on Vanoglipel (DA-1241) in Patients with Presumed MASH at the AASLD The Liver Meeting® 2025

Nov 6, 2025, 8:31 AM EST - 5 months ago

MetaVia Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 4, 2025, 4:01 PM EST - 5 months ago

MetaVia to Present New Phase 1 and Pre-Clinical Data on DA-1726 at ObesityWeek® 2025

Oct 27, 2025, 8:31 AM EDT - 5 months ago

MetaVia Announces Poster Presentation on Vanoglipel (DA-1241) at the AASLD Liver Meeting

Oct 20, 2025, 8:31 AM EDT - 6 months ago

MetaVia Announces Poster Presentations on DA-1726 at ObesityWeek® 2025

Oct 14, 2025, 8:31 AM EDT - 6 months ago

MetaVia to Present at the H.C. Wainwright Liver Disease Virtual Conference

Aug 26, 2025, 8:31 AM EDT - 8 months ago

MetaVia to Present at Upcoming Investor and Industry Conferences

Aug 7, 2025, 8:31 AM EDT - 8 months ago

MetaVia Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 6, 2025, 8:31 AM EDT - 8 months ago

MetaVia Extends 48 mg MAD Portion of Its Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity to 8 Weeks and Announces Fifth Weekly Dose in First Patient

Aug 4, 2025, 8:31 AM EDT - 8 months ago

MetaVia Announces AI-Driven Collaboration with Syntekabio to Explore Additional Indications for DA-1241

Jul 9, 2025, 8:31 AM EDT - 9 months ago

MetaVia Doses First Patient in the 48 mg MAD Cohort of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity to Further Explore Maximum Tolerated Dose

Jun 21, 2025, 9:00 AM EDT - 10 months ago

MetaVia Presents Pre-Clinical Data on DA-1241 Demonstrating Additive Hepatoprotective Effects in Combination With Efruxifermin at the ADA's 85th Scientific Session

Jun 10, 2025, 8:31 AM EDT - 10 months ago

MetaVia to Present at the Life Sciences Virtual Investor Forum June 12th

Jun 4, 2025, 8:31 AM EDT - 11 months ago

MetaVia Announces Poster Presentation on DA-1241 at the ADA's 85th Scientific Sessions

May 14, 2025, 4:05 PM EDT - 11 months ago

MetaVia Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 9, 2025, 8:01 AM EDT - 1 year ago

MetaVia Announces $10.0 Million Private Placement Priced At-The-Market under Nasdaq Rules

May 7, 2025, 2:00 AM EDT - 1 year ago

MetaVia Presents Data on DA-1241, a GPR119 Agonist, Demonstrating Both Hepatoprotective and Glucose-Regulating Effects in Patients with Presumed MASH, at the EASL Congress 2025

Apr 23, 2025, 8:31 AM EDT - 1 year ago

MetaVia Announces Late-Breaking Poster Presentation on DA-1241 at the EASL Congress 2025

Apr 22, 2025, 8:31 AM EDT - 1 year ago

MetaVia Reports Additional Positive Top-Line Results From the MAD Part 2 of Its Phase 1 Study of DA-1726, a Novel 3:1 Ratio GLP-1 and Glucagon Dual Receptor Agonist to Treat Obesity, Further Demonstrating Its Best-In-Class Potential

Apr 15, 2025, 7:01 AM EDT - 1 year ago

MetaVia Announces Positive Top-Line Data From the 4-Week Phase 1 MAD Trial of DA-1726, a Novel 3:1 Ratio GLP-1 Glucagon Dual Receptor Agonist to Treat Obesity, Showing Compelling Weight Loss and Safety Effects With Potential Best-In-Class Glucose Control (GLP-1R), Waist Reduction (GCGR), and Tolerability

Mar 20, 2025, 7:31 AM EDT - 1 year ago

MetaVia Reports Year End 2024 Financial Results and Provides Corporate Update

Jan 10, 2025, 8:05 AM EST - 1 year ago

MetaVia to Hold Advisory Committee Meeting at the 9th Annual MASH-TAG 2025 Conference

Nov 18, 2024, 8:01 AM EST - 1 year ago

NeuroBo Pharmaceuticals Announces Strategic Realignment Ahead of Important Clinical Milestones with Name Change to MetaVia - Reflecting the Company's Focus on Cardiometabolic Diseases

Nov 13, 2024, 8:01 AM EST - 1 year ago

NeuroBo Pharmaceuticals to Participate in Investor Conferences in November

Nov 7, 2024, 8:01 AM EST - 1 year ago

NeuroBo Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 4, 2024, 8:01 AM EST - 1 year ago

NeuroBo Pharmaceuticals Completes Last Patient Last Visit in Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH

Oct 1, 2024, 8:01 AM EDT - 1 year ago

NeuroBo Pharmaceuticals to Participate in Investor Conferences in October

Sep 30, 2024, 8:01 AM EDT - 1 year ago

NeuroBo Pharmaceuticals Announces Positive Top-Line Data From the SAD Part 1 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

Sep 3, 2024, 8:01 AM EDT - 1 year ago

NeuroBo to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Aug 14, 2024, 8:01 AM EDT - 1 year ago

NeuroBo Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 13, 2024, 8:01 AM EDT - 1 year ago

NeuroBo Pharmaceuticals Completes Enrollment of the SAD Part 1 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

Aug 6, 2024, 8:01 AM EDT - 1 year ago

NeuroBo Pharmaceuticals Announces Joint Research Agreement, Together with Dong-A ST and ImmunoForge to Develop a Long-Acting Once-Monthly Formulation of DA-1726 for the Treatment of Obesity

Jul 30, 2024, 8:01 AM EDT - 1 year ago

NeuroBo Pharmaceuticals Announces Exclusive License Agreement with MThera Pharma for NB-01

Jul 11, 2024, 8:01 AM EDT - 1 year ago

NeuroBo Pharmaceuticals to Present at the Emerging Growth Conference in July

Jun 26, 2024, 9:06 AM EDT - 1 year ago

NeuroBo Pharmaceuticals Doses First Patient in the MAD Part 2 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

Kertzi Apr. 11 at 5:31 AM

0 · Reply

Invest2Create Apr. 10 at 10:01 PM

0 · Reply

Coletrain02 Apr. 10 at 9:50 PM

$MTVA

0 · Reply

Joefreeagent Apr. 10 at 9:23 PM

$MTVA if you didn't get out before be happy with 20 cents and get out.

1 · Reply

SkOtTheBoOt Apr. 10 at 7:39 PM

$MTVA what about the people who are down over 80% in the last three months 🤔

0 · Reply

focafoca99 Apr. 10 at 6:07 PM

$MTVA dosed the first patient in the higher-dose part of its Phase 1 DA-1726 obesity study, testing titration paths to 48 mg and 64 mg.

0 · Reply

BioTuesdays Apr. 10 at 4:24 PM

0 · Reply

TheGreekOptions Apr. 10 at 4:05 PM

$MTVA Shares @ 1.35

0 · Reply

Mazhabib Apr. 10 at 3:20 PM

$MTVA

0 · Reply

DARKP00L Apr. 10 at 2:02 PM

$MTVA 08:35 on Apr. 10 2026 MetaVia Says First Patient Dosed In Part 3 Of Phase 1 Clinical Trial Evaluating DA-1726, Dual Oxyntomodulin Analog Targeting Both GLP-1 And Glucagon Receptors #tradeideas

0 · Reply

MrTicker Apr. 10 at 12:36 PM

$MTVA 16-Week Study Evaluates One-Step Dose Titration to 48 mg and Two-Step Dose Titration to 64 mg in Obese Otherwise Healthy Adults CAMBRIDGE, Mass., April 10, 2026 /PRNewswire/ -- MetaVia Inc.(MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that the first patient has been dosed in Part 3 of its Phase 1 clinical trial evaluating DA-1726, a novel dual oxyntomodulin (OXM) analog targeting both GLP-1 (GLP1R) and glucagon (GCGR) receptors. Part 3 of the Phase 1 program consists of two 16-week titration cohorts designed to evaluate one-step and two-step dose-escalation strategies to safely achieve higher target doses and further optimize tolerability.

0 · Reply

MrTicker Apr. 10 at 12:35 PM

$MTVA MetaVia Says First Patient Dosed In Part 3 Of Phase 1 Clinical Trial Evaluating DA-1726, Dual Oxyntomodulin Analog Targeting Both GLP-1 And Glucagon Receptors BENZINGA 7:35 AM ET 4/10/2026

0 · Reply

Kertzi Apr. 1 at 3:15 AM

⚠️ WARNING: $MTVA Paid Pump & Dump Alert ⚠️ @ZacksSCR is a known paid pumper; that is their business model. Companies pay hefty sums for these articles, which are supposedly "analyses." Zacks's target price for MTVA dropped from over $200 to $30. This is the best they can do, even though they’re being paid to hype it up.

0 · Reply

ZacksSCR Mar. 31 at 2:53 PM

$MTVA: Phase 1 Part 3 16-Week Titration Study of DA-1726 to Initiate in April 2026 https://buff.ly/a4OQaMH

0 · Reply

Joefreeagent Mar. 31 at 11:31 AM

$MTVA Maybe you think you can average down and make some money when it "goes to the moon." It won't, I'd be surprised if this is above a dollar by the end of April. It will be deficient, they will wait that out, file for an extension to remain listed. That will get approved. During that period the board will approve a reverse split and additional shares. That would be September-November. December they will announce results from their diet drug. Same day they will dilute with additional shares, warrants etc. They hate you. Stay away.

0 · Reply

rombrento Mar. 30 at 12:12 PM

$MTVA

0 · Reply

Kertzi Mar. 27 at 6:54 AM

$MTVA = NeuroBo $NRBO They changed their name to MetaVia in an attempt to hide NeuroBo Pharmaceutical's horrible history: In 2019, Korean company NeuroBo entered the U.S. Nasdaq market not through an initial public offering (IPO), but by acquiring a US based pharmaceutical firm on the brink of bankruptcy. Over the past seven years, the stock price has plummeted 100% annually, effectively erasing its value seven times. Initially, NeuroBo had its own IPRs, but they all failed! I’ve said it 100 times, but it bears repeating: MetaVia is now just an empty shell, a Puppet. It owns nothing (!), yet its Master, Dong-A ST, funds its own research, forcing MetaVia shareholders to pay for it through massive share dilution. Stay away from these kinds of stocks!

0 · Reply

WVU1 Mar. 25 at 5:51 PM

$MTVA Is this a buy that's the question ❓

3 · Reply

Kertzi Mar. 25 at 10:20 AM

⚠️ WARNING: $MTVA Paid Pump & Dump Alert ⚠️ DISCLAIMER: https://tinyurl.com/4pcth47a

1 · Reply

Kertzi Mar. 24 at 6:15 PM

$MTVA Share printing and dumping? OR Leaked news, e.g. FDA declined Vanoglipel meeting? We'll see... SCAM SCAM SHAAAAAM

1 · Reply

Jw242 Mar. 23 at 2:16 PM

$MTVA easy 10%. Thank you again shitavia

0 · Reply

Kertzi Mar. 22 at 9:41 AM

$MTVA People ask why the MC is only $4.67 million? = It's what the market assigns to a pre-revenue, licensing-based microcap with two early-stage candidates (Phase 1/2) and outsourced development, not to mention its notorious history of heavy dilution. ALL TIME HIGH : $1.4 MILLION PER SHARE (2017) The current cash balance is around $10 million, but advancing through Phases 2 and 3 would require Hundreds of Millions! What is the concrete plan to bridge that gap without further outrageous dilution?

0 · Reply

Market Cap	6.06M
Revenue (ttm)	0.00
Net Income (ttm)	-12.97M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	629,900
Avg Vol	229,132
Day's Range	N/A - N/A
Shares Out	5.09M
Stochastic %K	84%
Beta	0.35
Analysts	Strong Sell
Price Target	$19.33